Regulatory Response to Accelerate COVID-19 Drug Development

 

In a recent Journal for Clinical Studies article, Aman Khera and Henry J. Riordan, Ph.D., discuss recent guidance, operational processes and best practices designed by regulatory bodies to accelerate drug product development during COVID-19.

 

Questions regarding your upcoming clinical trial?